ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data
2001
ICI 182,780 (Fulvestrant™) for Advanced Breast Cancer
publication
Evidence: moderate
Author Information
Author(s): Robertson J F R
Primary Institution: Department of Surgery, City Hospital Nottingham
Hypothesis
ICI 182,780 is effective for treating advanced breast cancer in patients who have failed tamoxifen therapy.
Conclusion
ICI 182,780 is at least as effective as anastrozole for treating advanced breast cancer in patients who have progressed on prior endocrine therapy.
Supporting Evidence
- ICI 182,780 is the first in a new class of antioestrogens.
- Tamoxifen has been associated with detrimental effects and resistance.
- ICI 182,780 shows significant clinical activity in patients failing tamoxifen therapy.
- Phase III trials demonstrate ICI 182,780's effectiveness compared to anastrozole.
Takeaway
ICI 182,780 is a new medicine that helps women with advanced breast cancer, especially if other treatments didn't work.
Methodology
Phase III clinical trials were conducted to compare ICI 182,780 with anastrozole.
Participant Demographics
The study involved pre- and postmenopausal women with advanced breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website